Detalles de la búsqueda
1.
Joint modelling and simulation of M-protein dynamics and progression-free survival for alternative isatuximab dosing with pomalidomide/dexamethasone.
Br J Clin Pharmacol
; 88(5): 2052-2064, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-34705283
2.
Accelerating diagnosis of Parkinson's disease through risk prediction.
BMC Neurol
; 21(1): 201, 2021 May 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-34006233
3.
Using the SAEM algorithm for mechanistic joint models characterizing the relationship between nonlinear PSA kinetics and survival in prostate cancer patients.
Biometrics
; 73(1): 305-312, 2017 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-27148956
4.
Nonlinear joint models for individual dynamic prediction of risk of death using Hamiltonian Monte Carlo: application to metastatic prostate cancer.
BMC Med Res Methodol
; 17(1): 105, 2017 Jul 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-28716060
5.
Optimizing pharmacokinetic bridging studies in paediatric oncology using physiologically-based pharmacokinetic modelling: application to docetaxel.
Br J Clin Pharmacol
; 80(3): 534-47, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-26095234
6.
Evaluation of bootstrap methods for estimating uncertainty of parameters in nonlinear mixed-effects models: a simulation study in population pharmacokinetics.
J Pharmacokinet Pharmacodyn
; 41(1): 15-33, 2014 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-24317870
7.
Joint modeling of tumor dynamics and progression-free survival in advanced breast cancer: Leveraging data from amcenestrant early phase I-II trials.
CPT Pharmacometrics Syst Pharmacol
; 13(6): 941-953, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38558299
8.
A comparison of bootstrap approaches for estimating uncertainty of parameters in linear mixed-effects models.
Pharm Stat
; 12(3): 129-40, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-23457061
9.
Model-based simulation to support the approval of isatuximab alone or with dexamethasone for the treatment of relapsed/refractory multiple myeloma in Japanese patients.
CPT Pharmacometrics Syst Pharmacol
; 12(12): 1846-1858, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37002644
10.
Exposure-response analyses for selection/confirmation of optimal isatuximab dosing regimen in combination with pomalidomide/dexamethasone treatment in patients with multiple myeloma.
CPT Pharmacometrics Syst Pharmacol
; 11(6): 766-777, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35355430
11.
A mechanism-based model for the population pharmacokinetics of free and bound aflibercept in healthy subjects.
Br J Clin Pharmacol
; 72(3): 402-14, 2011 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-21575034
12.
PK/PD modeling analysis for dosing regimen selection of isatuximab as single agent and in combination therapy in patients with multiple myeloma.
CPT Pharmacometrics Syst Pharmacol
; 10(8): 928-940, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34185964
13.
Bayesian Individual Dynamic Predictions with Uncertainty of Longitudinal Biomarkers and Risks of Survival Events in a Joint Modelling Framework: a Comparison Between Stan, Monolix, and NONMEM.
AAPS J
; 22(2): 50, 2020 02 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-32076894
14.
Translational Model-Based Strategy to Guide the Choice of Clinical Doses for Antibody-Drug Conjugates.
J Clin Pharmacol
; 57(7): 865-875, 2017 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-28138963
15.
International randomized phase 2 study on the addition of docetaxel to the combination of cisplatin and 5-fluorouracil in the induction treatment for nasopharyngeal carcinoma in children and adolescents.
Cancer Chemother Pharmacol
; 77(2): 289-98, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26666649
16.
Nonlinear Mixed-effect Models for Prostate-specific Antigen Kinetics and Link with Survival in the Context of Metastatic Prostate Cancer: A Comparison by Simulation of Two-stage and Joint Approaches.
AAPS J
; 17(3): 691-9, 2015 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-25739818
17.
Population pharmacokinetic analysis of free and bound aflibercept in patients with advanced solid tumors.
Cancer Chemother Pharmacol
; 72(1): 167-80, 2013 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-23673444
18.
Phase I safety, pharmacokinetic and pharmacodynamic evaluation of the vascular disrupting agent ombrabulin (AVE8062) in patients with advanced solid tumors.
Clin Cancer Res
; 19(17): 4832-42, 2013 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-23833302
19.
Population pharmacokinetics and pharmacodynamics of enoxaparin in unstable angina and non-ST-segment elevation myocardial infarction.
Br J Clin Pharmacol
; 56(4): 407-14, 2003 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-12968985
Resultados
1 -
19
de 19
1
Próxima >
>>